Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults

Exclusion Criteria

• •Anti-AAV6 neutralizing antibodies
• •History of inhibitor to Factor VIII
• •Laboratory values at screening visit that are abnormal or outside acceptable study limits
• •Significant and/or unstable liver disease, biliary disease, significant liver fibrosis
• •Conditions associated with increased thromboembolic risk such as inherited or acquired thrombophilia, or a history of thrombotic events
• •Planned surgical procedure requiring Factor VIII surgical prophylactic factor treatment 12 months from screening visit
• •Active hepatitis B or C
• •Serological evidence of human immunodeficiency virus HIV-1 or HIV-2 with Cluster of Differentiation 4 positive (CD4+) cell count ≤200 mm3 and/or viral load \>20 copies/mL